Celcuity SEC Filings

Type
Report
Date
SCHEDULE 13D/ASCHEDULE 13D/A-Formular3/9/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/17/2026
SCHEDULE 13GSCHEDULE 13G-Formular2/17/2026
4Insidertransaktion2/13/2026
33-Formular2/13/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/12/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/12/2026
4Insidertransaktion1/29/2026
144144-Formular1/27/2026
SCHEDULE 13D/ASCHEDULE 13D/A-Formular1/16/2026
S-3ASRS-3ASR-Formular1/9/2026
4Insidertransaktion1/9/2026
4Insidertransaktion12/9/2025
4Insidertransaktion12/8/2025
144144-Formular12/5/2025
4Insidertransaktion12/3/2025
144144-Formular12/1/2025
4Insidertransaktion11/24/2025
4Insidertransaktion11/21/2025
144144-Formular11/21/2025
144144-Formular11/20/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/17/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/13/2025
10-QQuartalsbericht11/13/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/13/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/12/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/20/2025
D/AD/A-Formular9/23/2025
4Insidertransaktion9/15/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/10/2025
4Insidertransaktion9/10/2025
4Insidertransaktion9/4/2025
4Insidertransaktion8/20/2025
4Insidertransaktion8/20/2025
4Insidertransaktion8/20/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular8/18/2025
10-QQuartalsbericht8/14/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular8/4/2025
SCHEDULE 13GSCHEDULE 13G-Formular8/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/1/2025
SCHEDULE 13DSCHEDULE 13D-Formular8/1/2025
33-Formular8/1/2025
424B5424B5-Formular7/31/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/31/2025
305B2305B2-Formular7/31/2025
424B5424B5-Formular7/31/2025
4Insidertransaktion7/30/2025
FWPFWP-Formular7/30/2025
FWPFWP-Formular7/30/2025
424B5424B5-Formular7/29/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/29/2025
144144-Formular7/28/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/28/2025
424B5424B5-Formular7/28/2025
424B5424B5-Formular7/28/2025
144144-Formular7/28/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/30/2025
S-8S-8-Formular6/4/2025
4Insidertransaktion5/29/2025
4Insidertransaktion5/29/2025
4Insidertransaktion5/21/2025
4Insidertransaktion5/21/2025
4Insidertransaktion5/21/2025
4Insidertransaktion5/21/2025
4Insidertransaktion5/21/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/16/2025
10-QQuartalsbericht5/15/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/14/2025
4Insidertransaktion4/15/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4/7/2025
DEF 14ADEF 14A-Formular4/1/2025
ARSARS-Formular4/1/2025
DEFA14ADEFA14A-Formular4/1/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/31/2025
10-KJahresbericht3/31/2025
4Insidertransaktion3/5/2025
4Insidertransaktion2/18/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/11/2025
SCHEDULE 13GSCHEDULE 13G-Formular2/4/2025
4Insidertransaktion1/6/2025
424B5424B5-Formular12/6/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/6/2024
4Insidertransaktion12/3/2024
EFFECTEFFECT-Formular12/2/2024
S-3/AS-3/A-Formular11/26/2024
SC 13G/ABeneficial ownership report11/14/2024
SC 13G/ABeneficial ownership report11/14/2024
SC 13G/ABeneficial ownership report11/14/2024
10-QQuartalsbericht11/14/2024
SC 13GSC 13G-Formular11/14/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/14/2024
SC 13G/ABeneficial ownership report11/14/2024
4Insidertransaktion10/25/2024
D/AD/A-Formular10/15/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/9/2024

Celcuity Documents 2026

This page contains all official documents and SEC filings for Celcuity stock (CELC, ISIN: US15102K1007). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Celcuity's regulatory filings.

Celcuity Stock analysis

Celcuity Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide.